By Julia KarowThis article has been updated from a previous version to attribute Ambry's comments to the company's assistant medical director.
By a GenomeWeb staff reporter
Ambry Genetics will be the first authorized service provider for a new high-throughput target enrichment system being developed by RainDance Technologies, the companies announced last week.
By Justin Petrone
Growing demand for arrays designed to detect tumor copy-number changes is enticing more chip manufacturers to offer tools tailor-made for cancer research.
Ambry Genetics last week launched its CancerArray, an exon-focused, 180,000-probe array for comparative genomic hybridization.
Ambry's StemArray is manufactured by Roche NimbleGen and enables researchers studying stem cells to detect genomic abnormalities that would ordinarily be missed by low-resolution karyotyping.
CLG will sell the StemArray products and services to its current customers and other companies and research institutions.
Ambry Genetics is now able to offer all Roche NimbleGen applications, the first of Roche NimbleGen's growing list of service providers to achieve such certification.
Ambry is now certified on all Roche NimbleGen applications, offering services from its lab in California.
Under Ion Torrent's new service provider program, CSP certification means that the organization has been trained and tested by Ion Torrent to produce high quality sequence data.
Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.
The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.
In Science this week: genetic overlap among many psychiatric disorders, and more.
The Economist writes that an increasing number of scientific journals don't do peer review.